Remoxipride

Remoxipride

File:Remoxipride.svg
Systematic (IUPAC) name
3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide
Clinical data
Trade names	Roxiam
Legal status	Withdrawn
Routes of administration	Oral
Pharmacokinetic data
Bioavailability	96%
Protein binding	89-98%
Metabolism	Hepatic
Biological half-life	4-7 hours
Excretion	Renal
Identifiers
CAS Number	117591-79-4 N
ATC code	N05AL04 (WHO)
PubChem	CID: 54477
DrugBank	DB00409 Y
ChemSpider	49195 Y
UNII	0223RD59PE Y
KEGG	D02683 Y
ChEMBL	CHEMBL22242 Y
Chemical data
Formula	C16H23BrN2O3
Molecular mass	371.27 g/mol
SMILES CCN2CCC[C@H]2CNC(=O)c1c(OC)ccc(Br)c1OC
InChI InChI=1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)/t11-/m0/s1 Y Key:GUJRSXAPGDDABA-NSHDSACASA-N Y
NY (what is this?)  (verify)

Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients). It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993. Remoxipride acts as a selective D₂ and D₃ receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.

Due to its short half-life twice daily (bid) dosing is required, although a once-daily controlled-release tablet has been developed. There was some interest in its use in the treatment of treatment-resistant schizophrenia.

See also

• Typical antipsychotic
• Benzamide

External links

• Herbert Y. Meltzer, Atypical Antipsychotic Drugs, 2000